Summa Equity acquires majority stake in SG-based biotech firm Sengenics

Summa Equity acquires majority stake in SG-based biotech firm Sengenics

Summa Equity Fund II has acquired a majority stake in Singapore proteomics company Sengenics, paving the exit of SBI Islamic Fund II (Brunei).

SBI Islamic Fund II (Brunei) divested its 12.93 per cent stake in Sengenics to Summa Equity last month, the fund said in an undated press release on its website.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter